Harmony Biosciences Holdings
NasdaqGM:HRMY Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 93 Fair Values set on narratives written by author
WA
Consensus Narrative from 9 Analysts
Robust Late-Stage Pipeline Will Deliver New Therapies Over Next Five Years
Key Takeaways Robust pipeline and product launches are expected to drive substantial revenue growth and expand market presence over the coming years. Strong cash position enables further pipeline expansion and business development to enhance long-term earnings and shareholder value.
View narrativeUS$54.25
FV
36.3% undervalued intrinsic discount22.15%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
23 days ago author updated this narrative